Our findings imply that exploiting PFKFB3 as an autophagy flux mediator for therapeutic purposes could represent a novel combination treatment regimen against lung cancer tumors with intrinsic or acquired resistance to EGFR TKIs. Here, EGFR is linked to lung carcinoma.